GlassScriptPhysician profile
Andrew Bellantoni
NPI 1003278680
$1,120.34
in general payments reported to CMS, 2019-2025
16 companies · $60.35 in 2025
The $60.35 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $349 · 2024: $510 · 2025: $60.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $387.87 | 2023-2025 | |
| Y-Mabs Therapeutics, INC. | $122.73 | 2024 | Danyelza |
| Jazz Pharmaceuticals INC. | $121.08 | 2022 | |
| Servier Pharmaceuticals LLC | $110.92 | 2023-2024 | |
| Csl Behring | $64.04 | 2022-2023 | Hemgenix |
| Sobi, INC | $63.10 | 2022-2025 | |
| Amgen INC. | $57.80 | 2022-2023 | Blincyto |
| Pfizer INC. | $39.03 | 2023-2024 | |
| Uswm, LLC | $30.61 | 2024 | Iwilfin |
| Daiichi Sankyo INC. | $25.62 | 2024 | Injectafer |
| Biocon Biologics INC | $22.60 | 2024 | Fulphila |
| Kite Pharma, INC. | $21.53 | 2024 | Yescarta |
| Bio Products Laboratory USA, INC. | $20.40 | 2023 | Coagadex, Gammaplex |
| Rare Disease Therapeutics, INC. | $17.72 | 2023 | Purixan |
| Tempus Ai, INC | $15.29 | 2024 | Xt Cdx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bellantoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.